X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (156) 156
male (112) 112
infectious diseases (106) 106
adult (104) 104
female (94) 94
hiv infections - drug therapy (91) 91
middle aged (77) 77
antiretroviral therapy (65) 65
index medicus (56) 56
immunology (55) 55
hiv infection (53) 53
hiv infections - complications (41) 41
hiv (36) 36
anti-hiv agents - therapeutic use (34) 34
virology (32) 32
pharmacology & pharmacy (31) 31
antiretroviral therapy, highly active (30) 30
prospective studies (30) 30
hiv infections - virology (28) 28
microbiology (27) 27
cd4 lymphocyte count (26) 26
human-immunodeficiency-virus (26) 26
risk factors (26) 26
protease inhibitors (25) 25
treatment outcome (25) 25
aged (24) 24
anti-hiv agents - adverse effects (23) 23
antiretroviral therapy, highly active - adverse effects (21) 21
highly active antiretroviral therapy (20) 20
retrospective studies (18) 18
viral load (18) 18
aids (16) 16
hiv protease inhibitors - therapeutic use (16) 16
hiv-infected patients (16) 16
active antiretroviral therapy (15) 15
cohort studies (15) 15
disease (15) 15
efavirenz (15) 15
follow-up studies (15) 15
human immunodeficiency virus--hiv (15) 15
tenofovir (15) 15
virus diseases (15) 15
aids/hiv (14) 14
anti-hiv agents - administration & dosage (14) 14
antiretroviral drugs (14) 14
drug therapy (14) 14
prevalence (14) 14
reverse transcriptase inhibitors - therapeutic use (14) 14
safety (14) 14
therapy (14) 14
drug therapy, combination (13) 13
efficacy (13) 13
hiv infections - epidemiology (13) 13
hiv infections - immunology (13) 13
italy - epidemiology (13) 13
ritonavir - therapeutic use (13) 13
anti-retroviral agents - therapeutic use (12) 12
hiv-1 - drug effects (12) 12
protease inhibitor (12) 12
adolescent (11) 11
cross-sectional studies (11) 11
health aspects (11) 11
hiv protease inhibitors - adverse effects (11) 11
hiv-1-infected patients (11) 11
infected patients (11) 11
reverse-transcriptase inhibitors (11) 11
risk-factors (11) 11
epidemiology (10) 10
lipodystrophy (10) 10
adults (9) 9
antiretroviral therapy, highly active - methods (9) 9
antiviral agents (9) 9
care and treatment (9) 9
hiv patients (9) 9
hiv-1 (9) 9
hiv-1 - genetics (9) 9
italy (9) 9
lopinavir (9) 9
pharmacokinetics (9) 9
pravastatin (9) 9
reverse transcriptase inhibitors - adverse effects (9) 9
risk (9) 9
ritonavir (9) 9
statins (9) 9
time factors (9) 9
toxicity (9) 9
young adult (9) 9
hiv infections - blood (8) 8
hyperlipidemia (8) 8
infection (8) 8
inflammation (8) 8
lipids (8) 8
management (8) 8
nevirapine - therapeutic use (8) 8
raltegravir (8) 8
acquired immunodeficiency syndrome - complications (7) 7
adenine - analogs & derivatives (7) 7
aids-related opportunistic infections - epidemiology (7) 7
aids-related opportunistic infections - microbiology (7) 7
antiretroviral agents (7) 7
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Drug, Healthcare and Patient Safety, ISSN 1179-1365, 2009, Volume 1, Issue 1, pp. 25 - 33
Rosuvastatin represents the latest inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase introduced in clinical practice for the treatment of... 
Safety | Statin | LDL cholesterol | Pharmacokinetics | HMG-CoA reductase | Statins | Cholesterol
Journal Article
Journal Article
PLoS ONE, ISSN 1932-6203, 06/2017, Volume 12, Issue 6, p. e0179254
Objectives The study aim was to evaluate the impact on Liver and Kidney toxicity of the single tablet regimen Elvitegravir/Cobicistat/Emtricitabine/Tenofovir... 
REVERSE-TRANSCRIPTASE INHIBITOR | PATIENT-REPORTED SYMPTOMS | COFORMULATED ELVITEGRAVIR | MULTIDISCIPLINARY SCIENCES | NON-INFERIORITY TRIAL | CO-FORMULATED ELVITEGRAVIR | INITIAL TREATMENT | OPEN-LABEL | HIV-1 INFECTION | BOOSTED PROTEASE INHIBITOR | PHASE 3B | Emtricitabine - therapeutic use | Tenofovir - therapeutic use | HIV-1 - drug effects | HIV Infections - virology | Humans | Middle Aged | Male | Maximum Tolerated Dose | Quinolones - therapeutic use | Adult | Anti-HIV Agents - therapeutic use | Female | HIV Infections - drug therapy | Cobicistat - therapeutic use | Safety | Drug Combinations | Antiviral agents | Complications and side effects | Dosage and administration | Kidney failure | Research | Risk factors | Therapy | Toxicity | Liver | Transaminase | Chronic infection | Viruses | Infections | Tenofovir | Ethics | Hepatitis | Acquired immune deficiency syndrome--AIDS | Antiretroviral agents | Quality | Human immunodeficiency virus--HIV | Emtricitabine | Antiretroviral drugs | Alanine | Filtration | Kidneys | Epidermal growth factor receptors | Patients | Antiretroviral therapy | Glomerular filtration rate | Studies | Infectious diseases | Hospitals | Surveillance | Alanine transaminase | Aspartate aminotransferase | Kidney transplantation | Acquired immune deficiency syndrome | AIDS | HIV | Human immunodeficiency virus
Journal Article
Infection, ISSN 0300-8126, 10/2016, Volume 44, Issue 5, pp. 589 - 597
Journal Article
Clinical and Experimental Nephrology, ISSN 1342-1751, 11/2019, Volume 23, Issue 11, pp. 1272 - 1279
Chronic kidney disease (CKD) has become one of the most frequent non-infectious comorbidities in the aging HIV-infected population on long-standing combination... 
Antiretroviral drugs | Nephrology | Medicine & Public Health | Renal dysfunction | Albuminuria | Urology | Glomerular filtration rate | Proteinuria | HIV-1 | Prevalence | Age Factors | Humans | Middle Aged | Male | Protective Factors | Renal Insufficiency, Chronic - epidemiology | Ritonavir - therapeutic use | Adult | Anti-HIV Agents - therapeutic use | Female | Dideoxynucleosides - therapeutic use | Retrospective Studies | Hypertension - epidemiology | Integrase Inhibitors - therapeutic use | Drug Therapy, Combination | Glomerular Filtration Rate | Albuminuria - etiology | Cross-Sectional Studies | Tenofovir - therapeutic use | HIV Infections - virology | Risk Factors | CD4 Lymphocyte Count | Renal Insufficiency, Chronic - physiopathology | Hypertriglyceridemia - epidemiology | Diabetes Mellitus - epidemiology | Sex Factors | HIV Infections - drug therapy | Italy - epidemiology | Hypertension | Medical research | Care and treatment | Clinics | Comorbidity | Communicable diseases | HIV (Viruses) | Highly active antiretroviral therapy | Chronic kidney failure | Protease inhibitors | Proteases | Medicine, Experimental | Diabetes | Integrase | Renal function | Epidermal growth factor receptors | Ritonavir | Diabetes mellitus | Triglycerides | Proteinase inhibitors | Epidemiology | Risk factors | Antiretroviral therapy | CD4 antigen | Tenofovir | Cell number | Human immunodeficiency virus--HIV | Abacavir | Aging | Kidney diseases | Drug therapy
Journal Article
Journal Article
Clinical and Experimental Nephrology, ISSN 1342-1751, 2/2014, Volume 18, Issue 1, pp. 104 - 112
Journal Article
Journal of Antimicrobial Chemotherapy, ISSN 0305-7453, 07/2017, Volume 72, Issue 7, pp. 2138 - 2140
Journal Article
Journal Article
Retrovirology, ISSN 1742-4690, 05/2010, Volume 7, Issue S1, pp. P83 - P83
Journal Article
International Journal of STD & AIDS, ISSN 0956-4624, 4/2019, Volume 30, Issue 5, pp. 467 - 471
Raltegravir (RAL) is an HIV-1 integrase strand transfer inhibitor that is well established as a component of highly active antiretroviral therapy regimens for... 
human immunodeficiency virus | treatment | combination antiretroviral therapy | Antiretroviral therapy | viral disease | INFECTIOUS DISEASES | IMMUNOLOGY | TENOFOVIR/EMTRICITABINE
Journal Article
Current HIV Research, ISSN 1570-162X, 2016, Volume 14, Issue 1, pp. 61 - 70
Journal Article